Methylation of the phosphate oxygen moiety of phospholipid‐methoxy(polyethylene glycol) conjugate prevents PEGylated liposome‐mediated complement activation and anaphylatoxin production

Methoxy(polyethylene glycol), mPEG,‐grafted liposomes are known to exhibit prolonged circulation time in the blood, but their infusion into a substantial percentage of human subjects triggers immediate non‐IgE‐mediated hypersensitivity reactions. These reactions are strongly believed to arise from anaphylatoxin production through complement activation. Despite the general view that vesicle surface camouflaging with mPEG should dramatically suppress complement activation, here we show that bilayer enrichment of noncomplement activating liposomes [dipalmitoylphosphatidylcholine (DPPC) vesicles] with phospholipid‐mPEG conjugate induces complement activation resulting in vesicle recognition by macrophage complement receptors. The extent of vesicle uptake, however, is dependent on surface mPEG density. We have delineated the likely structural features of phospholipid‐mPEG conjugate responsible for PEGylated liposome‐induced complement activation in normal as well as C1q‐deficient human sera, using DPPC vesicles bearing the classical as well as newly synthesized lipid‐mPEG conjugates. With PEGylated DPPC vesicles, the net anionic charge on the phosphate moiety of phospholipid‐mPEG conjugate played a key role in activation of both classical and alternative pathways of complement and anaphylatoxin production (reflected in significant rises in SC5b‐9, C4d, and C3a‐desarg levels in normal human sera as well as SC5b‐9 in EGTA‐chelated/Mg2+ supplemented serum), since methylation of the phosphate oxygen of phospholipid‐mPEG conjugate, and hence the removal of the negative charge, totally prevented complement activation. To further corroborate on the role of the negative charge in complement activation, vesicles bearing anionic phospholipid‐mPEG conjugates, but not the methylated phospholipid‐mPEG, were shown to significantly decrease serum hemolytic activity and increase plasma thromboxane B2 levels in rats. In contrast to liposomes, phospholipid‐mPEG micelles had no effect on complement activation, thus suggesting a possible role for vesicular zwitterionic phospholipid head‐groups as an additional factor contributing to PEGylated liposome‐mediated complement activation. Our findings provide a rational conceptual basis for development of safer vesicles for site‐specific drug delivery and controlled release at pathological sites.—Moghimi, S. M., Hamad, I., Andresen, T. L., Jørgensen, K., Szebeni, J. Methylation of the phosphate oxygen moiety of phospholipid‐methoxy(polyethylene glycol) conjugate prevents PEGylated liposome‐mediated complement activation and anaphylatoxin production FASEB J. 20, E2057–E2067 (2006)

[1]  S. Moghimi,et al.  PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance , 2002, FEBS letters.

[2]  C. Alving,et al.  Potentiation of liposome-induced complement activation by surface-bound albumin. , 2002, Biochimica et biophysica acta.

[3]  C. Chesterman,et al.  Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[4]  T. Andresen,et al.  Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2. , 2005, Current drug delivery.

[5]  C. Alving,et al.  Antibodies to cholesterol, cholesterol conjugates and liposomes: implications for atherosclerosis and autoimmunity. , 1991, Critical reviews in immunology.

[6]  S. Moghimi,et al.  The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes. , 2006, Biomaterials.

[7]  J. Szebeni.  Complement Activation-Related Pseudoallergy , 2004 .

[8]  J. Brash,et al.  Protein adsorption to polyethylene glycol modified liposomes from fibrinogen solution and from plasma. , 2001, Biochimica et biophysica acta.

[9]  D. Devine,et al.  Liposome-complement interactions in rat serum: implications for liposome survival studies. , 1994, Biochimica et biophysica acta.

[10]  U. Kishore,et al.  Modular Organization of the Carboxyl-Terminal, Globular Head Region of Human C1q A, B, and C Chains1 , 2003, The Journal of Immunology.

[11]  Y. Barenholz,et al.  Electrostatics of PEGylated micelles and liposomes containing charged and neutral lipopolymers. , 2005, Langmuir : the ACS journal of surfaces and colloids.

[12]  S. Moein Moghimi,et al.  Recognition by Macrophages and Liver Cells of Opsonized Phospholipid Vesicles and Phospholipid Headgroups , 2004, Pharmaceutical Research.

[13]  P. Cullis,et al.  Drug Delivery Systems: Entering the Mainstream , 2004, Science.

[14]  O. G. Mouritsen,et al.  Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs. , 2004, Journal of medicinal chemistry.

[15]  J. Jensenius,et al.  Regulation of the Mannan-Binding Lectin Pathway of Complement on Neisseria gonorrhoeae by C1-Inhibitor and α2-Macroglobulin1 , 2002, The Journal of Immunology.

[16]  F M Muggia,et al.  Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  S. Moghimi,et al.  Modulation of murine liver macrophage clearance of liposomes by diethylstilbestrol. The effect of vesicle surface charge and a role for the complement receptor Mac-1 (CD11b/CD18) of newly recruited macrophages in liposome recognition. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[18]  M. Bodó,et al.  Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. , 2006, American journal of physiology. Heart and circulatory physiology.

[19]  Christine Gaboriaud,et al.  The Crystal Structure of the Globular Head of Complement Protein C1q Provides a Basis for Its Versatile Recognition Properties* , 2003, Journal of Biological Chemistry.

[20]  F M Muggia,et al.  Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Bally,et al.  Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. , 1998, Biochimica et biophysica acta.

[22]  A. C. Hunter,et al.  Nanomedicine: current status and future prospects , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  Alving Cr,et al.  Antibodies to cholesterol, cholesterol conjugates and liposomes: implications for atherosclerosis and autoimmunity. , 1991 .

[24]  M. Bally,et al.  Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). , 2001, Biochimica et biophysica acta.

[25]  F M Muggia,et al.  ROLE OF COMPLEMENT ACTIVATION IN HYPERSENSITIVITY REACTIONS TO DOXIL AND HYNIC PEG LIPOSOMES: EXPERIMENTAL AND CLINICAL STUDIES , 2002, Journal of liposome research.

[26]  Y. Barenholz,et al.  Hydration of polyethylene glycol-grafted liposomes. , 1998, Biophysical journal.

[27]  N. Thielens,et al.  Structure and activation of the C1 complex of complement: unraveling the puzzle. , 2004, Trends in immunology.

[28]  C. Alving,et al.  Complement activation in human serum by liposome-encapsulated hemoglobin: the role of natural anti-phospholipid antibodies. , 1996, Biochimica et biophysica acta.

[29]  Klint,et al.  Binding of Immune Complexes to Erythrocyte CR1 (CD35): Difference in Requirement of Classical Pathway Components and Indication of Alternative Pathway‐Mediated Binding in C2‐Deficiency , 2000, Scandinavian journal of immunology.

[30]  D. Devine,et al.  C1q binding to liposomes is surface charge dependent and is inhibited by peptides consisting of residues 14-26 of the human C1qA chain in a sequence independent manner. , 1999, Biochimica et biophysica acta.

[31]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[32]  D. Devine,et al.  The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. , 1991, Journal of immunology.

[33]  U. Kishore,et al.  Modular Organization of the Carboxyl-Terminal, Globular Head Region of Human C1q A, B, and C Chains1 , 2003, The Journal of Immunology.

[34]  T. Andresen,et al.  Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. , 2005, Progress in lipid research.

[35]  D. Devine,et al.  Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids. , 1998, Archives of biochemistry and biophysics.

[36]  D. Needham,et al.  Range and magnitude of the steric pressure between bilayers containing phospholipids with covalently attached poly(ethylene glycol). , 1995, Biophysical journal.

[37]  C. Alving,et al.  Complement activation in vitro by the red cell substitute, liposome‐ encapsulated hemoglobin: mechanism of activation and inhibition by soluble complement receptor type 1 , 1997, Transfusion.

[38]  J Szebeni,et al.  Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. , 2003, Progress in lipid research.

[39]  C. Alving,et al.  Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation. , 1994, Biochemical and biophysical research communications.

[40]  M. Bodó,et al.  Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. , 2000, American journal of physiology. Heart and circulatory physiology.

[41]  M. Frank,et al.  C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I , 1984, The Journal of experimental medicine.

[42]  D. Fearon,et al.  Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase. , 1982, Journal of immunology.

[43]  H. Kaplan,et al.  Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells , 2003, Nature Medicine.

[44]  M. Bodó,et al.  The interaction of liposomes with the complement system: in vitro and in vivo assays. , 2003, Methods in enzymology.

[45]  H. Lutz,et al.  The Role of Complement Activation in Hypersensitivity to Pegylated Liposomal Doxorubicin (Doxil®) , 2000 .